Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures

NCT ID: NCT02129309

Last Updated: 2015-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2014-12-31

Brief Summary

The investigators are interested in studying how Pulmonary Hypertension occurs. A substance called 'apelin', that naturally occurs in the body has been shown to have an important role in heart disease. Previous studies have shown that it can make blood vessels get wider, and help blood flow around the body and thus improve the way the heart and lungs work.

The investigators are looking to recruit both healthy and COPD pulmonary hypertension patients to study 3 types of apelin. The purpose of this study is to help the investigators understand how Pulmonary Hypertension occurs which may will help with the development of future treatments.

Detailed Description

The purpose of this study:

To investigate the physiological role of apelin in the cardiovascular system in patients with COPD with raised pulmonary artery pressures.

Study Aim and hypotheses:

The primary objective is to test the above hypotheses using forearm blood flow and systemic infusions of apelin peptides.

Hypotheses:

1. Apelin agonists are vasodilators in human resistance vessels and this effect will be altered in patients with pulmonary hypertension.

2. Apelin peptides improve right ventricular and pulmonary haemodynamics in patients with elevated pulmonary artery pressures.

Study 1a - A validation dose study of 3 apelin agonists performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 1b- A validation dose study of apelin receptor antagonist, in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 2a - To define the haemodynamic response to apelin agonists in healthy volunteers and evaluate the response.

Study 2b - To investigate the haemodynamic response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures.

Conditions

COPD; Pulmonary Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Systemic Apelin infusion

Study 2a - Haemodynamic studies to investigate the response to systemic infusions of 3 apelin agonists in healthy volunteers

Study 2b - Haemodynamic studies to investigate the response to 3 apelin agonists in COPD patients with elevated pulmonary artery pressures

Group Type: EXPERIMENTAL

Haemodynamic studies

Intervention Type: PROCEDURE

Dose response study

Apelin infusion - forearm

Study 1a - A validation dose study of 3 apelin agonists using forearm plethysmography to evaluate changes in forearm blood flow: performed in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Study 1b- A validation dose study of apelin receptor antagonist using forearm plethysmography to evaluate changes in forearm blood flow, in healthy volunteers and COPD patients with elevated pulmonary artery pressures.

Group Type: EXPERIMENTAL

Forearm plethysmography

Intervention Type: PROCEDURE

Dose response study

Interventions

Forearm plethysmography

Dose response study

Intervention Type: PROCEDURE

Haemodynamic studies

Dose response study

Intervention Type: PROCEDURE

Other Intervention Names

Innocor; Bioimpedance; Echocardiography

Eligibility Criteria

Inclusion Criteria

• Healthy volunteers

• Aged 18 to 70 years
• Non-smoker (<1 cigarette per week)
• If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test COPD patients with estimated Pulmonary Artery Pressure (PAP) on echo >25mmHg
• Clinical diagnosis of COPD as per standard criteria
• Between 18 and 70 years
• If female, postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test

Exclusion Criteria

• pre-existing:

• Systemic Hypertension (sustained BP >160/100mmHg)
• Ischaemic Heart Disease
• Primary valvular heart disease
• Significant left ventricular failure
• Active malignancy
• Renal disease (Creatinine >180 µmol/L)
• Neurological disease
• Diabetes mellitus
• BMI >35, BMI <17
• Pregnancy
• Use of vasoactive medication or NSAIDS/aspirin within 48 hours of study.
• Current involvement in other research studies, other than observational/non-interventional
• Known HIV

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Wellcome Trust

OTHER

Sponsor Role: collaborator

University of Cambridge

OTHER

Sponsor Role: collaborator

Cambridge University Hospitals NHS Foundation Trust

OTHER

Sponsor Role: lead

Responsible Party

Joseph Cheriyan, MD

Consultant Physician & Clinical Pharmacologist

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dr. Joseph Cheriyan, MD

Role: PRINCIPAL_INVESTIGATOR

Cambridge University Hospitals NHS Foundation Trust

Locations

Vascular Research Unit, Clinical Pharmacology Unit, ACCI, Level 3, Addenbrooke's Hospital, Hills Road

Cambridge, , United Kingdom

Countries

United Kingdom

Other Identifiers

ALPHa-COPD

Identifier Type: -

Identifier Source: org_study_id